

Steven N Goodman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4249951/publications.pdf>

Version: 2024-02-01

136
papers

22,561
citations

30551

56
h-index

15253

130
g-index

148
all docs

148
docs citations

148
times ranked

32777
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating mutant DNA to assess tumor dynamics. <i>Nature Medicine</i> , 2008, 14, 985-990.	15.2	2,207
2	Redefine statistical significance. <i>Nature Human Behaviour</i> , 2018, 2, 6-10.	6.2	1,763
3	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. <i>European Journal of Epidemiology</i> , 2016, 31, 337-350.	2.5	1,761
4	Very high risk of cancer in familial Peutz-Jeghers syndrome. <i>Gastroenterology</i> , 2000, 119, 1447-1453.	0.6	1,247
5	Detection and quantification of mutations in the plasma of patients with colorectal tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 16368-16373.	3.3	1,049
6	Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy. <i>Annals of Internal Medicine</i> , 1999, 130, 995.	2.0	935
7	Pancreaticoduodenectomy for Cancer of the Head of the Pancreas 201 Patients. <i>Annals of Surgery</i> , 1995, 221, 721-733.	2.1	884
8	What does research reproducibility mean?. <i>Science Translational Medicine</i> , 2016, 8, 341ps12.	5.8	804
9	Toward Evidence-Based Medical Statistics. 2: The Bayes Factor. <i>Annals of Internal Medicine</i> , 1999, 130, 1005.	2.0	732
10	The Use of Predicted Confidence Intervals When Planning Experiments and the Misuse of Power When Interpreting Results. <i>Annals of Internal Medicine</i> , 1994, 121, 200.	2.0	543
11	Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2111417.	2.8	460
12	A Dirty Dozen: Twelve P-Value Misconceptions. <i>Seminars in Hematology</i> , 2008, 45, 135-140.	1.8	459
13	Some practical improvements in the continual reassessment method for phase I studies. <i>Statistics in Medicine</i> , 1995, 14, 1149-1161.	0.8	457
14	An Ethics Framework for a Learning Health Care System: A Departure from Traditional Research Ethics and Clinical Ethics. <i>Hastings Center Report</i> , 2013, 43, S16-27.	0.7	420
15	Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer's Disease: A Systematic Review. <i>Neuroepidemiology</i> , 2004, 23, 159-169.	1.1	369
16	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. <i>Blood</i> , 2010, 115, 3224-3230.	0.6	346
17	Random-Effects Meta-analysis of Inconsistent Effects: A Time for Change. <i>Annals of Internal Medicine</i> , 2014, 160, 267-270.	2.0	344
18	RNAi-Mediated Silencing of Nuclear Factor Erythroid-2-Related Factor 2 Gene Expression in Non-Small Cell Lung Cancer Inhibits Tumor Growth and Increases Efficacy of Chemotherapy. <i>Cancer Research</i> , 2008, 68, 7975-7984.	0.4	331

#	ARTICLE	IF	CITATIONS
19	Sensitive digital quantification of DNA methylation in clinical samples. <i>Nature Biotechnology</i> , 2009, 27, 858-863.	9.4	317
20	Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change. <i>Annals of Internal Medicine</i> , 2009, 151, 206.	2.0	293
21	p Values, Hypothesis Tests, and Likelihood: Implications for Epidemiology of a Neglected Historical Debate. <i>American Journal of Epidemiology</i> , 1993, 137, 485-496.	1.6	285
22	A comment on replication,P-values and evidence. <i>Statistics in Medicine</i> , 1992, 11, 875-879.	0.8	260
23	Manuscript Quality before and after Peer Review and Editing at <i>Annals of Internal Medicine</i> . <i>Annals of Internal Medicine</i> , 1994, 121, 11.	2.0	252
24	Causal Inference in Public Health. <i>Annual Review of Public Health</i> , 2013, 34, 61-75.	7.6	251
25	Assessing scientists for hiring, promotion, and tenure. <i>PLoS Biology</i> , 2018, 16, e2004089.	2.6	244
26	Quantitation of Promoter Methylation of Multiple Genes in Urine DNA and Bladder Cancer Detection. <i>Journal of the National Cancer Institute</i> , 2006, 98, 996-1004.	3.0	237
27	Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1185.	3.8	209
28	The Researchâ€treatment Distinction: <i>A Problematic Approach for Determining Which Activities Should Have Ethical Oversight</i>. <i>Hastings Center Report</i> , 2013, 43, S4-S15.	0.7	203
29	The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. <i>Annals of Internal Medicine</i> , 2020, 172, 35.	2.0	203
30	Meta-research: Evaluation and Improvement of Research Methods and Practices. <i>PLoS Biology</i> , 2015, 13, e1002264.	2.6	202
31	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. <i>Nature Communications</i> , 2021, 12, 2349.	5.8	194
32	Reproducible Research: Moving toward Research the Public Can Really Trust. <i>Annals of Internal Medicine</i> , 2007, 146, 450.	2.0	191
33	Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. <i>Human Pathology</i> , 1996, 27, 119-124.	1.1	186
34	Catalytic Asymmetric Total Syntheses of Quinine and Quinidine. <i>Journal of the American Chemical Society</i> , 2004, 126, 706-707.	6.6	170
35	Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 30-38.	3.2	158
36	Acne therapy: A methodologic review. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 231-240.	0.6	148

#	ARTICLE	IF	CITATIONS
37	The Methods of Comparative Effectiveness Research. <i>Annual Review of Public Health</i> , 2012, 33, 425-445.	7.6	139
38	A blinded, crossover study of the efficacy of the ketogenic diet. <i>Epilepsia</i> , 2009, 50, 322-325.	2.6	126
39	An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA. <i>Clinical Cancer Research</i> , 2011, 17, 4494-4503.	3.2	126
40	Introduction to Bayesian methods I: measuring the strength of evidence. <i>Clinical Trials</i> , 2005, 2, 282-290.	0.7	123
41	Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 1370-5.	3.2	120
42	Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1634-1637.	3.0	110
43	Prevention of thromboembolism in atrial fibrillation. <i>Journal of General Internal Medicine</i> , 2000, 15, 56-67.	1.3	108
44	High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i> , 2010, 115, 2136-2141.	0.6	107
45	How and why studies disagree about the effects of education on health: A systematic review and meta-analysis of studies of compulsory schooling laws. <i>Social Science and Medicine</i> , 2018, 212, 168-178.	1.8	106
46	How Statistical Expertise Is Used in Medical Research. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 2817.	3.8	104
47	Random-Effects Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 301.	3.8	103
48	Statistical reviewing policies of medical journals. <i>Journal of General Internal Medicine</i> , 1998, 13, 753-756.	1.3	93
49	What Patients Say about Medical Research. <i>IRB: Ethics & Human Research</i> , 1998, 20, 1.	0.8	87
50	Five ways to fix statistics. <i>Nature</i> , 2017, 551, 557-559.	13.7	86
51	Aligning statistical and scientific reasoning. <i>Science</i> , 2016, 352, 1180-1181.	6.0	75
52	Harms From Uninformative Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 813.	3.8	70
53	Why Most Published Research Findings Are False: Problems in the Analysis. <i>PLoS Medicine</i> , 2007, 4, e168.	3.9	70
54	Phase II Study of Risk-Adapted Therapy of Newly Diagnosed, Aggressive Non-Hodgkin Lymphoma Based on Midtreatment FDG-PET Scanning. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 242-248.	2.0	64

#	ARTICLE	IF	CITATIONS
55	Enantiopure $\hat{1}^2$ -Hydroxy Morpholine Amides from Terminal Epoxides by Carbonylation at 1 atm. <i>Angewandte Chemie - International Edition</i> , 2002, 41, 4703-4705.	7.2	62
56	Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 705.	3.8	58
57	Raw data from clinical trials: within reach?. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 645-647.	4.0	57
58	Toward protecting the safety of participants in clinical trials. <i>Contemporary Clinical Trials</i> , 2003, 24, 256-271.	2.0	56
59	Association of Rapid Eye Movement Sleep With Mortality in Middle-aged and Older Adults. <i>JAMA Neurology</i> , 2020, 77, 1241.	4.5	55
60	Considering Usual Medical Care in Clinical Trial Design. <i>PLoS Medicine</i> , 2009, 6, e1000111.	3.9	54
61	Stopping at Nothing? Some Dilemmas of Data Monitoring in Clinical Trials. <i>Annals of Internal Medicine</i> , 2007, 146, 882.	2.0	53
62	Purpose and Benefits of Early Phase Cancer Trials: What Do Oncologists Say? What Do Patients Hear?. <i>Journal of Empirical Research on Human Research Ethics</i> , 2008, 3, 57-68.	0.6	51
63	Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer. <i>Journal of Urology</i> , 2008, 179, 743-747.	0.2	48
64	Calibrating the Scientific Ecosystem Through Meta-Research. <i>Annual Review of Statistics and Its Application</i> , 2020, 7, 11-37.	4.1	48
65	Probability at the Bedside: The Knowing of Chances or the Chances of Knowing?. <i>Annals of Internal Medicine</i> , 1999, 130, 604.	2.0	46
66	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	1.3	46
67	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020, 9, 1193.	0.8	41
68	Machine Learning, Health Disparities, and Causal Reasoning. <i>Annals of Internal Medicine</i> , 2018, 169, 883.	2.0	40
69	Preprint Servers's Policies, Submission Requirements, and Transparency in Reporting and Research Integrity Recommendations. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1901.	3.8	40
70	A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barre. <i>Clinical Trials</i> , 2005, 2, 305-310.	0.7	39
71	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020, 9, 1193.	0.8	38
72	Why is Getting Rid of P -Values So Hard? Musings on Science and Statistics. <i>American Statistician</i> , 2019, 73, 26-30.	0.9	37

#	ARTICLE	IF	CITATIONS
73	Disclosure of Individual Surgeon's Performance Rates During Informed Consent. <i>Annals of Surgery</i> , 2007, 245, 507-513.	2.1	36
74	An intervention to improve cancer patients' understanding of early-phase clinical trials. <i>IRB: Ethics & Human Research</i> , 2009, 31, 1-10.	0.8	34
75	Data monitoring committees for pragmatic clinical trials. <i>Clinical Trials</i> , 2015, 12, 530-536.	0.7	32
76	How often do leading biomedical journals use statistical experts to evaluate statistical methods? The results of a survey. <i>PLoS ONE</i> , 2020, 15, e0239598.	1.1	32
77	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. <i>PLoS ONE</i> , 2013, 8, e68966.	1.1	31
78	Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research. <i>Clinical Trials</i> , 2016, 13, 621-631.	0.7	27
79	Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. <i>The Cochrane Library</i> , 2006, , CD001938.	1.5	26
80	Role and limitations of epidemiology in establishing a causal association. <i>Seminars in Cancer Biology</i> , 2004, 14, 413-426.	4.3	25
81	What patients say about medical research. <i>IRB: Ethics & Human Research</i> , 1998, 20, 1-7.	0.8	25
82	Using big data analytics to extract disease surveillance information from point of care diagnostic machines. <i>Pervasive and Mobile Computing</i> , 2017, 42, 470-486.	2.1	23
83	Ethical Issues in Evidence-Based Surgery. <i>Surgical Clinics of North America</i> , 2006, 86, 151-168.	0.5	21
84	Ethical Considerations in Studying Drug Safety "The Institute of Medicine Report. <i>New England Journal of Medicine</i> , 2012, 367, 959-964.	13.9	21
85	COVID-19 Clinical Trials: A Teachable Moment for Improving Our Research Infrastructure and Relevance. <i>Annals of Internal Medicine</i> , 2020, 173, 652-653.	2.0	20
86	Commentary: The P-value, devalued. <i>International Journal of Epidemiology</i> , 2003, 32, 699-702.	0.9	19
87	Stopping trials for efficacy: an almost unbiased view. <i>Clinical Trials</i> , 2009, 6, 133-135.	0.7	18
88	Closing in on the Truth About Recombinant Human Bone Morphogenetic Protein-2: Evidence Synthesis, Data Sharing, Peer Review, and Reproducible Research. <i>Annals of Internal Medicine</i> , 2013, 158, 916.	2.0	18
89	Bias and Trials Stopped Early for Benefit. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 156.	3.8	17
90	Bayesian Communication: A Clinically Significant Paradigm for Electronic Publication. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2000, 7, 254-266.	2.2	16

#	ARTICLE	IF	CITATIONS
91	Systematic reviews are not biased by results from trials stopped early for benefit. <i>Journal of Clinical Epidemiology</i> , 2008, 61, 95-96.	2.4	16
92	How sure are you of your result? Put a number on it. <i>Nature</i> , 2018, 564, 7-7.	13.7	15
93	Inappropriate Statistical Analysis and Reporting in Medical Research: Perverse Incentives and Institutional Solutions. <i>Annals of Internal Medicine</i> , 2018, 169, 577.	2.0	15
94	Statistical Code to Support the Scientific Story. <i>Annals of Internal Medicine</i> , 2018, 168, 828-829.	2.0	15
95	All That Glitters Isn't Gold: A Survey on Acknowledgment of Limitations in Biomedical Studies. <i>PLoS ONE</i> , 2013, 8, e73623.	1.1	14
96	Lost Evidence From Registered Large Long-Unpublished Randomized Controlled Trials: A Survey. <i>Annals of Internal Medicine</i> , 2019, 171, 300.	2.0	14
97	The high resource impact of reformatting requirements for scientific papers. <i>PLoS ONE</i> , 2019, 14, e0223976.	1.1	13
98	The Role of Masks in Mitigating the SARS-CoV-2 Pandemic: Another Piece of the Puzzle. <i>Annals of Internal Medicine</i> , 2021, 174, 419-420.	2.0	13
99	Discussion: An estimate of the science-wise false discovery rate and application to the top medical literature. <i>Biostatistics</i> , 2014, 15, 23-27.	0.9	12
100	Diastolic Blood Pressure Levels and Ischemic Stroke Incidence in Older Adults With White Matter Lesions. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2011, 66A, 74-81.	1.7	11
101	U.S. Food and Drug Administration Reasoning in Approval Decisions When Efficacy Evidence Is Borderline, 2013-2018. <i>Annals of Internal Medicine</i> , 2021, 174, 1603-1611.	2.0	10
102	How large should the next study be? Predictive power and sample size requirements for replication studies. <i>Statistics in Medicine</i> , 2022, 41, 3090-3101.	0.8	10
103	Future prospects discussed. <i>Nature</i> , 1994, 368, 106-107.	13.7	9
104	Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2005, 11, 8413-8417.	3.2	9
105	Quasi-random reflections on randomized controlled trials and comparative effectiveness research. <i>Clinical Trials</i> , 2012, 9, 22-26.	0.7	9
106	Advances in Regulatory Science at the Food and Drug Administration. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2103.	3.8	9
107	Opening the FDA Black Box. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 361.	3.8	9
108	Should Psychology Journals Adopt Specialized Statistical Review?. <i>Advances in Methods and Practices in Psychological Science</i> , 2019, 2, 240-249.	5.4	9

#	ARTICLE	IF	CITATIONS
109	The Methodologic Ozone Effect. <i>Epidemiology</i> , 2005, 16, 430-435.	1.2	8
110	Building a Bayesian Bridge From Evidence to Guidelines. <i>Archives of Internal Medicine</i> , 2009, 169, 1436.	4.3	7
111	Clinical Trial Data Sharing: What Do We Do Now?. <i>Annals of Internal Medicine</i> , 2015, 162, 308.	2.0	7
112	Ethics and evidence in clinical trials. <i>Clinical Trials</i> , 2005, 2, 195-196.	0.7	6
113	Bayesian Methods for Evidence Evaluation. <i>Circulation</i> , 2013, 127, 2367-2369.	1.6	5
114	<i>Annals</i> Understanding Clinical Research: Interpreting Results With Large P Values. <i>Annals of Internal Medicine</i> , 2018, 169, 485-486.	2.0	5
115	Randomized COVID-19 vaccination rollout can offer direct real-world evidence. <i>Journal of Clinical Epidemiology</i> , 2021, 138, 199-202.	2.4	5
116	One-sided or two-sided p values?. <i>Contemporary Clinical Trials</i> , 1988, 9, 387-388.	2.0	4
117	Confessions of a chagrined trialist. <i>BMJ Quality and Safety</i> , 2011, 20, i97-i98.	1.8	4
118	Urodynamic factors associated with the large capacity bladder and incomplete emptying after prolapse repair (2009-2015). <i>Neurourology and Urodynamics</i> , 2019, 38, 1322-1331.	0.8	4
119	Analysis of Subgroup Effects in Randomized Trials When Subgroup Membership is Missing: Application to the Second Multicenter Automatic Defibrillator Intervention Trial. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2011, 60, 607-617.	0.5	3
120	Rashomon revisited: two views of monitoring the Women's Health Initiative trials. <i>Clinical Trials</i> , 2007, 4, 205-206.	0.7	2
121	Commentary. <i>Biostatistics</i> , 2010, 11, 389-390.	0.9	2
122	Sharing Clinical Research Data—Finding the Right Balance. <i>JAMA Internal Medicine</i> , 2017, 177, 1241.	2.6	2
123	Lack of Diagnostic Utility of α -Amino Acid Dysregulation Metabotypes. <i>Biological Psychiatry</i> , 2019, 85, e41-e42.	0.7	2
124	The Mammography Dilemma. <i>Annals of Internal Medicine</i> , 2003, 138, 771.	2.0	2
125	On making clinical trials possible. <i>Clinical Trials</i> , 2010, 7, 621-621.	0.7	1
126	Harry Marks: an appreciation. <i>Clinical Trials</i> , 2011, 8, 123-127.	0.7	1

#	ARTICLE	IF	CITATIONS
127	Letter to the Editor: Bayesian analysis for a single 2 ^{Ã—} 2 table by L. Hashemi, B. Nandram and R. Goldberg, <i>Statistics in Medicine</i> , 16, 1311-1328 (1997). , 1998, 17, 2147-2148.		0
128	Landmark clinical trials: a new journal series. <i>Clinical Trials</i> , 2011, 8, 128-128.	0.7	0
129	A decade of <i>Clinical Trials</i>. <i>Clinical Trials</i> , 2013, 10, 837-839.	0.7	0
130	Posing Causal Questions When Analyzing Observational Dataâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 201.	3.8	0
131	2007 The clinical research operations program: Educating clinical research staff. <i>Journal of Clinical and Translational Science</i> , 2018, 2, 61-61.	0.3	0
132	Random-Effects Assumption in Meta-analysesâ€™Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 82.	3.8	0
133	Title is missing!. , 2020, 15, e0239598.		0
134	Title is missing!. , 2020, 15, e0239598.		0
135	Title is missing!. , 2020, 15, e0239598.		0
136	Title is missing!. , 2020, 15, e0239598.		0